During the recent session, Lyell Immunopharma Inc (NASDAQ:LYEL)’s traded shares were 0.63 million, with the beta value of the company hitting -0.36. At the last check today, the stock’s price was $0.60, reflecting an intraday gain of 3.68% or $0.02. The 52-week high for the LYEL share is $3.26, that puts it down -443.33 from that peak though still a striking 15.0% gain since the share price plummeted to a 52-week low of $0.51. The company’s market capitalization is $176.29M, and the average intraday trading volume over the past 10 days was 1.72 million shares, and the average trade volume was 1.27 million shares over the past three months.
Lyell Immunopharma Inc (LYEL) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 3.33. LYEL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.13.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Lyell Immunopharma Inc (LYEL) registered a 3.68% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.68% in intraday trading to $0.60, hitting a weekly high. The stock’s 5-day price performance is 5.20%, and it has moved by 1.04% in 30 days. Based on these gigs, the overall price performance for the year is -65.62%. The short interest in Lyell Immunopharma Inc (NASDAQ:LYEL) is 11.53 million shares and it means that shorts have 14.5 day(s) to cover.
The consensus price target of analysts on Wall Street is $1, which implies an increase of 40.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $1 respectively. As a result, LYEL is trading at a discount of -66.67% off the target high and -66.67% off the low.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
In the rating firms’ projections, revenue will decrease -59.23% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.28%. While earnings are projected to return 21.51% in 2025, the next five years will return 17.62% per annum.
LYEL Dividends
Lyell Immunopharma Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Lyell Immunopharma Inc insiders own 13.72% of total outstanding shares while institutional holders control 58.89%, with the float percentage being 68.25%. MWG MANAGEMENT LTD. is the largest shareholder of the company, while 155.0 institutions own stock in it. As of 2024-06-30, the company held over 20.16 million shares (or 7.9301% of all shares), a total value of $29.24 million in shares.
The next largest institutional holding, with 15.09 million shares, is of ORLAND PROPERTIES LTD’s that is approximately 5.9366% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $21.89 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lyell Immunopharma Inc (LYEL) shares are Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 5.82 shares. This amounts to just over 1.99 percent of the company’s overall shares, with a $3.49 million market value. The same data shows that the other fund manager holds slightly less at 5.4, or about 1.85% of the stock, which is worth about $3.24 million.
